Skip to content

European Dyspnoea Survey in the EMergency Departments

European Dyspnoea Survey in the EMergency Departments

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02060799
Acronym
EuroDEM
Enrollment
2156
Registered
2014-02-12
Start date
2014-02-28
Completion date
2014-11-30
Last updated
2014-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspnea, Emergencies

Keywords

Dyspnea, Emergency Service, Hospital, prognosis, Fatal Outcome, Epidemiology

Brief summary

Braunwald defines dyspnoea as an abnormally uncomfortable awareness of breathing. Breathing discomfort, and its varying degrees of severity, is the one of the most disturbing symptoms patients can experience; and it is one of the main complaints in the patients presenting to the Emergency Department (ED). Dyspnea has a variety of underlying etiologies, like cardiac, pulmonary or metabolic etiologies or a combination of them, since several diseases can cause dyspnea like for instance heart failure (HF), asthma and chronic obstructive pulmonary disease (COPD). Acute heart failure syndrome (AHFS) is collectively defined as a gradual or rapid change in heart failure (HF) signs and symptoms resulting in a need for urgent therapy. Heart failure (HF) is one of the most important causes of morbidity and mortality in the industrialized world. The prevalence of symptomatic HF is estimated to range from 0.4 to 2.0% in general European population. The incidence increases rapidly with age, and in Europe. Characteristics, clinical presentation, treatment, and outcomes of HF patients admitted to hospital have been adequately described, in Europe and in the United States. The Euro Heart Failure Survey (EHFS) I with 11 327 patients described the demographics of acutely hospitalized HF patients. The ADHERE registry has data on over 100 000 hospitalizations for AHF from the USA. In-hospital mortality was 4 and 7%, in ADHERE and EHFS I, respectively. This same sensation of breathlessness is what also drives patients with asthma and chronic obstructive pulmonary disease (COPD) to the ED. Chronic obstructive pulmonary disease (COPD) exacerbation accounts for approximately 1.5 million ED visits in the United States per year. It is the third most common cause of hospitalization, with an estimated 726 000 hospitalizations in 2000 in the USA. Previous studies have demonstrated important differences between guideline recommendations and actual management of COPD exacerbation, either in the ED or during hospitalization. The diagnosis in front of a dyspneic patient in the ED remains a challenge, because of a low sensitivity of the clinical signs associated with the aging of the population and the variety of underlying diseases. Little is known about the Epidemiology of dyspneic patients in the ED at the European level. Diagnosis, prevalence and treatment of the patients may vary among European countries.

Detailed description

MAIN OBJECTIVES * Epidemiologic description of patients presenting to the ED with shortness of breath as main complaint. * Description of current management in the ED of patients presenting to the ED with shortness of breath as main complaint. SECONDARY OBJECTIVES * Sub analysis of ED discharged patients versus admitted patients for characteristics, comparison to recommended care and re-ED visit. * Determine clinical and/or biological criteria to distinguish between: * Patients who are treated as outpatients and admitted patients. * Patients hospitalized in ward and patients admitted to intensive care units (CCU and ICU) * Prognostic prediction, using clinical and biochemical data * To determine if ED patients treated for acute heart failure differ from those admitted to hospital. * Comparison of European data characteristics, investigation, treatment and outcome to similar data in other part of the world.

Interventions

None listed

Sponsors

Hopital Lariboisière
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Consecutive patients presenting to the Emergency Department with Dyspnea as main complaint * 18 years or older

Exclusion criteria

* No acceptance to participate from the patient

Design outcomes

Primary

MeasureTime frameDescription
All cause mortality30 daysAll cause mortality will be evaluated 30 days after ED visit.

Secondary

MeasureTime frame
All cause rehospitalization30 days

Other

MeasureTime frameDescription
ED visit30 daysNew ED visit during follow-up

Countries

Belgium, Finland, France, Germany, Italy, Netherlands, Romania, Spain, Turkey (Türkiye), United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026